Compare Charles River Laboratories Intl. Inc (CRL) vs iShares Core High Dividend ETF (HDV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Charles River Laboratories Intl. Inc vs iShares Core High Dividend ETF — how do they compare? Charles River Laboratories Intl. Inc trades at $303.99 (market cap $14.23B), while iShares Core High Dividend ETF trades at $28.74 (market cap $14.68B). The key difference: Charles River Laboratories Intl. Inc and iShares Core High Dividend ETF are close in size by market cap, and Charles River Laboratories Intl. Inc is trading nearer its 52-week high, iShares Core High Dividend ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Charles River Laboratories Intl. Inc for 33 Days and iShares Core High Dividend ETF for 117 Days on average.
| CRL | HDV | |
|---|---|---|
Market Cap | $14.23B | $14.68B |
Volume | 1,176,885 | 2,925,562 |
Sector | Health | — |
52-Week High | $310.77 | $29.93 |
52-Week Low | $149.93 | $23.64 |
Typical Hold Time | 33 Days | 117 Days |
Enterprise Value | $17.06B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $300.53, up 0.08% on the day, with a bullish technical outlook and strong analyst support. The stock has consistently beaten earnings estimates in recent quarters, though it faces profitability challenges with a negative net income margin and ROE. Recent investor day presentations highlighted a strategic plan targeting 5-7% revenue growth and $300 million in savings by 2030, driving positive sentiment.
The outlook is cautiously optimistic, supported by analyst buy ratings and a $305.50 consensus price target, but risks include ongoing margin pressure, volatile non-human primate costs, and a high valuation multiple. Earnings growth and successful execution of the new strategic plan are critical for sustained upside.
HDV (iShares Core High Dividend ETF) trades at $28.73, up 1.59% with strong bullish technical signals from moving averages and oscillators. The ETF recently underwent a significant sector rebalancing, reducing healthcare exposure while increasing energy, staples, and utilities. Recent dividend payments of $0.06-$0.10 per share demonstrate consistent income generation, though the 3% yield may not fully compensate for increased concentration risk.
The outlook remains cautiously optimistic given the bullish technical setup and sector rotation benefits, but investors face risks from heightened concentration in three sectors (62% allocation) and potential yield compression. The ETF's performance relative to peers like VYM suggests competitive positioning, though sector concentration requires monitoring for diversification adequacy.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →About iShares Core High Dividend ETF
The fund generally will invest at least 80% of its assets in the component securities of its underlying index and in investments that have economic characteristics that are substantially identical to the component securities of its underlying index. The underlying index is comprised of qualified income paying securities that are screened for superior company quality and financial health as determined by Morningstar, Inc.'s proprietary index methodology. The fund is non-diversified.
Read more on HDV →
